Literature DB >> 22171203

A novel therapy for REM sleep behavior disorder (RBD).

Michael J Howell1, Patricia A Arneson, Carlos H Schenck.   

Abstract

STUDY
OBJECTIVES: RBD may result in sleep related injury (SRI) particularly if a patient exits the bed during dream enactment behavior (DEB). The complex auditory processing and low arousal threshold of REM sleep offers a therapeutic window to halt behavior prior to SRI. We evaluated whether a recorded message prevents SRI in medically refractory RBD.
DESIGN: Case Series.
SETTING: Sleep disorders center. PATIENTS: Four consecutive RBD patients with continued SRI despite both clonazepam and melatonin therapy. INTERVENTION: A pressurized bed alarm customized with a familiar voice to deliver a calming message during vigorous DEB. MEASUREMENTS AND
RESULTS: The RBDQ-HK evaluated RBD symptoms, and SRI was further quantified with a new clinical tool, the Minnesota Parasomnia Injury Scale. All patients reported a decrease in RBD symptoms and SRI. No injuries occurred post-intervention. Pre-treatment: 5 serious events (SE), 80 minor events (ME), and 193 near events (NE) were noted over 66 patient-months (4.21 events/pt-mo). Post-treatment: 0 SE, 0 ME, and 3 NE were noted after a follow up period of 63 pt-months (0.05 event/pt-mo). There were 176 total bed alarm interventions (2.79 interventions/pt-mo). No adverse effects were reported, and all 4 patients described a minimal burden of treatment. RBD symptoms improved as the average RBDQ-HK score decreased from 68 (range: 53-80) to 54 (range 42-65).
CONCLUSION: A customized bed alarm may be an effective method to prevent SRI in RBD. This intervention is most suitable for cases of medically refractory RBD and/or for those patients who are unable to tolerate medical therapy.

Entities:  

Keywords:  Minnesota Parasomnia Injury Scale; Parkinson disease; REM sleep behavior disorder; bed alarm; clonazepam; melatonin

Mesh:

Substances:

Year:  2011        PMID: 22171203      PMCID: PMC3227710          DOI: 10.5664/jcsm.1470

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  28 in total

1.  Obstructive sleep apnea syndrome induced by clonazepam in a narcoleptic patient with REM-sleep-behavior disorder.

Authors:  A Schuld; T Kraus; M Haack; D Hinze-Selch; T Pollmächer
Journal:  J Sleep Res       Date:  1999-12       Impact factor: 3.981

Review 2.  Paradoxical sleep and its chemical/structural substrates in the brain.

Authors:  B E Jones
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

3.  A polysomnographic and clinical report on sleep-related injury in 100 adult patients.

Authors:  C H Schenck; D M Milner; T D Hurwitz; S R Bundlie; M W Mahowald
Journal:  Am J Psychiatry       Date:  1989-09       Impact factor: 18.112

4.  Ontogenetic variations in auditory arousal threshold during sleep.

Authors:  K A Busby; L Mercier; R T Pivik
Journal:  Psychophysiology       Date:  1994-03       Impact factor: 4.016

5.  A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder.

Authors:  Dieter Kunz; Richard Mahlberg
Journal:  J Sleep Res       Date:  2010-12       Impact factor: 3.981

Review 6.  Parasomnias: epidemiology and management.

Authors:  Laurel Wills; John Garcia
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

7.  Melatonin therapy for REM sleep behavior disorder.

Authors:  N Takeuchi; N Uchimura; Y Hashizume; M Mukai; Y Etoh; K Yamamoto; T Kotorii; H Ohshima; M Ohshima; H Maeda
Journal:  Psychiatry Clin Neurosci       Date:  2001-06       Impact factor: 5.188

8.  Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients.

Authors:  Bradley F Boeve; Michael H Silber; Tanis J Ferman
Journal:  Sleep Med       Date:  2003-07       Impact factor: 3.492

Review 9.  Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.

Authors:  Guy Chouinard
Journal:  J Clin Psychiatry       Date:  2004       Impact factor: 4.384

10.  Chronic behavioral disorders of human REM sleep: a new category of parasomnia.

Authors:  C H Schenck; S R Bundlie; M G Ettinger; M W Mahowald
Journal:  Sleep       Date:  1986-06       Impact factor: 5.849

View more
  27 in total

1.  Sleepwalking.

Authors:  Valérie Cochen De Cock
Journal:  Curr Treat Options Neurol       Date:  2016-02       Impact factor: 3.598

Review 2.  Rapid eye movement sleep behavior disorder and the link to alpha-synucleinopathies.

Authors:  Daniel A Barone; Claire Henchcliffe
Journal:  Clin Neurophysiol       Date:  2018-05-29       Impact factor: 3.708

3.  Neurodegenerative Disease and REM Behavior Disorder.

Authors:  Raman Malhotra; Alon Y Avidan
Journal:  Curr Treat Options Neurol       Date:  2012-10       Impact factor: 3.598

4.  Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia.

Authors:  D Aarsland; C Ballard; A Rongve; M Broadstock; P Svenningsson
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

Review 5.  Parasomnias.

Authors:  John A Fleetham; Jonathan A E Fleming
Journal:  CMAJ       Date:  2014-05-05       Impact factor: 8.262

Review 6.  Treatment of REM Sleep Behavior Disorder.

Authors:  Youngsin Jung; Erik K St Louis
Journal:  Curr Treat Options Neurol       Date:  2016-11       Impact factor: 3.598

7.  Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease.

Authors:  Yan Wang; Yuechang Yang; Huijuan Wu; Danmei Lan; Ying Chen; Zhongxin Zhao
Journal:  J Clin Sleep Med       Date:  2016-10-15       Impact factor: 4.062

8.  Dream enactment behavior: review for the clinician.

Authors:  Marc Baltzan; Chun Yao; Dorrie Rizzo; Ron Postuma
Journal:  J Clin Sleep Med       Date:  2020-11-15       Impact factor: 4.062

9.  Sleep dysfunction in multiple system atrophy.

Authors:  Luigi Ferini-Strambi; Sara Marelli
Journal:  Curr Treat Options Neurol       Date:  2012-10       Impact factor: 3.598

Review 10.  Parasomnias: an updated review.

Authors:  Michael J Howell
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.